Health Care [ 9/12 ] | Biotechnology [ 43/75 ]
NASDAQ | Common Stock
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a.
Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis.
CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 16, 26 | -0.88 Decreased by -10.00% | -0.70 Decreased by -25.41% |
| Nov 7, 25 | -0.84 Decreased by -53.79% | -0.46 Decreased by -82.61% |
| Aug 8, 25 | -0.70 Decreased by -159.26% | -0.68 Decreased by -2.94% |
| Jun 13, 25 | -0.56 Decreased by -36.59% | -0.62 Increased by +10.16% |
| Mar 31, 25 | -0.80 Decreased by -110.53% | -0.63 Decreased by -26.12% |
| Nov 11, 24 | -0.55 Increased by +21.97% | -0.41 Decreased by -33.22% |
| Aug 9, 24 | -0.27 Increased by +82.62% | -0.31 Increased by +12.90% |
| May 14, 24 | -0.41 Increased by +79.60% | -0.39 Decreased by -5.13% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 8.73 K Decreased by -99.60% | -8.09 M Decreased by -20.60% | Decreased by -92.68 K% Decreased by -29.78 K% |
| Sep 30, 25 | 322.57 K Decreased by -83.37% | -7.73 M Decreased by -62.54% | Decreased by -2.40 K% Decreased by -877.58% |
| Jun 30, 25 | 1.76 M Decreased by -46.56% | -6.26 M Decreased by -170.12% | Decreased by -356.05% Decreased by -405.44% |
| Mar 31, 25 | 1.92 M Decreased by -18.32% | -4.89 M Decreased by -94.65% | Decreased by -255.30% Decreased by -138.31% |
| Dec 31, 24 | 2.16 M Decreased by -13.21% | -6.71 M Decreased by -183.86% | Decreased by -310.17% Decreased by -227.06% |
| Sep 30, 24 | 1.94 M Increased by +27.13% | -4.75 M Decreased by -321.06% | Decreased by -245.03% Decreased by -273.88% |
| Jun 30, 24 | 3.29 M Increased by +N/A% | -2.32 M Decreased by -62.53% | Decreased by -70.44% Decreased by N/A% |
| Mar 31, 24 | 2.35 M Increased by +66.69% | -2.51 M Decreased by -370.55% | Decreased by -107.13% Decreased by -182.29% |